Diabetes study shows nothing new, says journal editorBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39294.547326.DB (Published 02 August 2007) Cite this as: BMJ 2007;335:223
- Janice Hopkins Tanne
- New York
Vivian Fonseca, the editor of Diabetes Care, told the BMJ that he was surprised by the media's interest in a study that says that rosiglitazone (Avandia) and pioglitazone (Actos) doubled the risk of heart failure in patients with type 2 diabetes (Diabetes Care 2007;30:2148-53 doi: 10.2337/dc07-0141).
The authors said that although drugs in the thiazolidinedione class were known to increase the risk of heart failure in patients with type 2 diabetes, the magnitude of the risk had not been evaluated. They used teleoanalysis to look at results …